Shanxi Securities gives Aimeike a "Buy" rating, with short-term performance under pressure. The company’s ability to independently develop and acquire to layout the entire medical aesthetics industry chain is promising.

Everyday Economic News AI Express. On March 31, Shanxi Securities released a research report saying it gives a “Buy” rating to Aimeike (300896.SZ, latest price: 117.24 yuan). The main reasons for the rating include: 1) During the period, revenue for the company’s solution and gel products declined to varying degrees, affected by factors such as the macro environment and industry competition; 2) Independent R&D + outbound M&A strengthen the company’s industrial layout and integration capabilities; 3) M&A and subsequent integration of international aesthetic medicine targets accelerate the company’s deep integration into global aesthetic medicine industry chain division of labor and cooperation. Risk warning: risk of intense market competition; risk of changes in industry regulatory policies; risk that sales of new products will not meet expectations.

Everyday Economic News Headline (nbdtoutiao) — With AI “lobster” stock trading, some investors claim “an astonishing track record of earning 90% per month”; some people lose 80,000 yuan despite investing 200,000 yuan! Reporter investigation: Can ordinary people play?

(Reporter Zeng Jianhui)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before using. If you act on this, you bear the risks.

Daily Economic News